[
  {
    "ts": null,
    "headline": "AbbVie Shares Hit Record High on Rinvoq Exclusivity Extension to 2037",
    "summary": "Extra four years of exclusivity boosts long-term growth outlook",
    "url": "https://finnhub.io/api/news?id=c341ac73d1c2d6665a5c6c8d1e853877702662b6d4f4185e4466da1770c5aa4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757702895,
      "headline": "AbbVie Shares Hit Record High on Rinvoq Exclusivity Extension to 2037",
      "id": 136726567,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Extra four years of exclusivity boosts long-term growth outlook",
      "url": "https://finnhub.io/api/news?id=c341ac73d1c2d6665a5c6c8d1e853877702662b6d4f4185e4466da1770c5aa4a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Hit a Record on ‘Big Win’ for Blockbuster Drug. The Case for Buying In.",
    "summary": "Shares of  AbbVie  closed at a record after it struck a deal that will extend patent exclusivity for its blockbuster autoimmune medicine Rinvoq until 2037.  The patent extension is a positive for AbbVie as it continues to deal with declining sales of its former cash cow Humira, which lost patent protection in 2023.  It’s a “big win for Rinvoq,” said William Blair analysts led by Matt Phipps.",
    "url": "https://finnhub.io/api/news?id=8ce900ac9f7ece04dccf6003a11208c941876634c4d77c68eed1e12c8c32a7ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757689020,
      "headline": "AbbVie Stock Hit a Record on ‘Big Win’ for Blockbuster Drug. The Case for Buying In.",
      "id": 136726568,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Shares of  AbbVie  closed at a record after it struck a deal that will extend patent exclusivity for its blockbuster autoimmune medicine Rinvoq until 2037.  The patent extension is a positive for AbbVie as it continues to deal with declining sales of its former cash cow Humira, which lost patent protection in 2023.  It’s a “big win for Rinvoq,” said William Blair analysts led by Matt Phipps.",
      "url": "https://finnhub.io/api/news?id=8ce900ac9f7ece04dccf6003a11208c941876634c4d77c68eed1e12c8c32a7ca"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock",
    "summary": "ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.",
    "url": "https://finnhub.io/api/news?id=a1ec1ae61613d11406cd0066252bff369cc80a2884208951370aaa6a6b53b448",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757686860,
      "headline": "AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock",
      "id": 136726544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.",
      "url": "https://finnhub.io/api/news?id=a1ec1ae61613d11406cd0066252bff369cc80a2884208951370aaa6a6b53b448"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Sep 12, 2025",
    "summary": "Companies in The News Are: TSLA, WBD, DOW, ABBV",
    "url": "https://finnhub.io/api/news?id=9212290e93839809b9d62a53505aa8b77ee7fa22bbf6d40a0824e31377356a89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757686680,
      "headline": "Company News for Sep 12, 2025",
      "id": 136726541,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Companies in The News Are: TSLA, WBD, DOW, ABBV",
      "url": "https://finnhub.io/api/news?id=9212290e93839809b9d62a53505aa8b77ee7fa22bbf6d40a0824e31377356a89"
    }
  },
  {
    "ts": null,
    "headline": "Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff",
    "summary": "Genmab A/S is a solid buy with undervalued stock, robust royalties, and blockbuster ADC potential. Click for my look at GMAB and why I am bullish.",
    "url": "https://finnhub.io/api/news?id=4e100d5d1e4e7ce1a426e12289f957dfb35d0d7ac16accbec1d533d924bf9936",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757685521,
      "headline": "Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff",
      "id": 136726915,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2199361189/image_2199361189.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Genmab A/S is a solid buy with undervalued stock, robust royalties, and blockbuster ADC potential. Click for my look at GMAB and why I am bullish.",
      "url": "https://finnhub.io/api/news?id=4e100d5d1e4e7ce1a426e12289f957dfb35d0d7ac16accbec1d533d924bf9936"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie settles litigation with all generic manufacturers of Rinvoq",
    "summary": "AbbVie (ABBV) announced that it has settled litigation with all generic manufacturers that filed abbreviated new drug applications with the Food and Drug Administration for generic versions of upadacitinib tablets, which AbbVie markets as Rinvoq. “Given the settlement and license agreements, which are subject to standard acceleration provisions, assuming pediatric exclusivity is granted, no generic entry for any upadacitinib tablets is expected prior to April 2037 in the United States,” the comp",
    "url": "https://finnhub.io/api/news?id=8fba77227e28fd05b0aaa2a459de4fbda3bc6db3292fb360b434bde2663fb465",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757685338,
      "headline": "AbbVie settles litigation with all generic manufacturers of Rinvoq",
      "id": 136711278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) announced that it has settled litigation with all generic manufacturers that filed abbreviated new drug applications with the Food and Drug Administration for generic versions of upadacitinib tablets, which AbbVie markets as Rinvoq. “Given the settlement and license agreements, which are subject to standard acceleration provisions, assuming pediatric exclusivity is granted, no generic entry for any upadacitinib tablets is expected prior to April 2037 in the United States,” the comp",
      "url": "https://finnhub.io/api/news?id=8fba77227e28fd05b0aaa2a459de4fbda3bc6db3292fb360b434bde2663fb465"
    }
  },
  {
    "ts": null,
    "headline": "What Looms Ahead After The Dow Jones Topped A Record Of 46,000",
    "summary": "Dow Jones hits record 46,000 amid tech and AI gains. What does this mean for investors for the rest of this year? Read the full analysis here.",
    "url": "https://finnhub.io/api/news?id=7368aed8560d1a68ee92c89e62e983ce65e339a65d34a6156618d09607b13226",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757684698,
      "headline": "What Looms Ahead After The Dow Jones Topped A Record Of 46,000",
      "id": 136726369,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1854380206/image_1854380206.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Dow Jones hits record 46,000 amid tech and AI gains. What does this mean for investors for the rest of this year? Read the full analysis here.",
      "url": "https://finnhub.io/api/news?id=7368aed8560d1a68ee92c89e62e983ce65e339a65d34a6156618d09607b13226"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie extends Rinvoq exclusivity by four years after generics settlements",
    "summary": "AbbVie has signed deals with Rinvoq generic hopefuls as it extends protection for one of its prized assets until 2037.",
    "url": "https://finnhub.io/api/news?id=32b6f15c80adbd9438c2e748827beee6e1283eed216258b30c6bac8599ec7b3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757679956,
      "headline": "AbbVie extends Rinvoq exclusivity by four years after generics settlements",
      "id": 136711279,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie has signed deals with Rinvoq generic hopefuls as it extends protection for one of its prized assets until 2037.",
      "url": "https://finnhub.io/api/news?id=32b6f15c80adbd9438c2e748827beee6e1283eed216258b30c6bac8599ec7b3c"
    }
  },
  {
    "ts": null,
    "headline": "The Best Stocks to Invest $50,000 In Right Now",
    "summary": "These stocks have what it takes to succeed over the long run.",
    "url": "https://finnhub.io/api/news?id=7eb23a8972813ac8b71f89e5119402b51378f4e1585cb9e614efc4b6857f2922",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757670360,
      "headline": "The Best Stocks to Invest $50,000 In Right Now",
      "id": 136711128,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "These stocks have what it takes to succeed over the long run.",
      "url": "https://finnhub.io/api/news?id=7eb23a8972813ac8b71f89e5119402b51378f4e1585cb9e614efc4b6857f2922"
    }
  },
  {
    "ts": null,
    "headline": "Genmab: A Matter Of Time",
    "summary": "Genmab raised the full-year revenue and operating income guidance after strong Q2 results. Click here to find out why GMAB stock is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=89e681d96912b65a847ad7583779d497e5cb9edf50760a5768663d57f87ebd95",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757657700,
      "headline": "Genmab: A Matter Of Time",
      "id": 136710105,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1375897245/image_1375897245.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Genmab raised the full-year revenue and operating income guidance after strong Q2 results. Click here to find out why GMAB stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=89e681d96912b65a847ad7583779d497e5cb9edf50760a5768663d57f87ebd95"
    }
  }
]